Homology Medicines to Participate in Upcoming Investor Conferences
August 04 2021 - 8:30AM
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic
medicines company, announced today participation in fireside chats
at the following virtual conferences:
- BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m.
ET
- Canaccord Genuity 41st Annual Growth Conference: August 11 at
9:00 a.m. ET
The webcast presentation from the Canaccord conference will be
accessible on Homology’s website in the Investors section, and the
webcast replay will be available on the website for 90 days
following the presentation.
About Homology Medicines, Inc.Homology
Medicines, Inc. is a clinical-stage genetic medicines company
dedicated to transforming the lives of patients suffering from rare
diseases by targeting the underlying cause of the disease. The
Company’s lead clinical program, HMI-102, is a gene therapy for
adults with phenylketonuria (PKU) and additional programs focus on
lysosomal storage disorders including Hunter syndrome, paroxysmal
nocturnal hemoglobinuria (PNH) and other diseases. Homology’s
proprietary platform is designed to utilize its family of 15 human
hematopoietic stem cell-derived adeno-associated virus vectors
(AAVHSCs) to precisely and efficiently deliver genetic medicines in
vivo through a gene therapy or nuclease-free gene editing modality,
as well as to deliver one-time gene therapy to produce antibodies
throughout the body through the GTx-mAb platform. Homology has a
management team with a successful track record of discovering,
developing and commercializing therapeutics with a focus on rare
diseases and believes that its data, internal manufacturing
capabilities and broad intellectual property position the Company
as a leader in genetic medicines. For more information, visit
www.homologymedicines.com.
Company ContactsTheresa McNeelyChief
Communications Officer and Patient
Advocatetmcneely@homologymedicines.com781-301-7277
Media Contact:Cara Mayfield Vice President,
Patient Advocacy and Corporate Communications
cmayfield@homologymedicines.com 781-691-3510
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Apr 2023 to Apr 2024